248 related articles for article (PubMed ID: 10214734)
1. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
Neumann PJ; Hermann RC; Kuntz KM; Araki SS; Duff SB; Leon J; Berenbaum PA; Goldman PA; Williams LW; Weinstein MC
Neurology; 1999 Apr; 52(6):1138-45. PubMed ID: 10214734
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
Fuh JL; Wang SJ
Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
López-Bastida J; Hart W; García-Pérez L; Linertová R
J Alzheimers Dis; 2009; 16(2):399-407. PubMed ID: 19221429
[TBL] [Abstract][Full Text] [Related]
7. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
8. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Getsios D; Blume S; Ishak KJ; Maclaine GD
Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
Knapp M; King D; Romeo R; Adams J; Baldwin A; Ballard C; Banerjee S; Barber R; Bentham P; Brown RG; Burns A; Dening T; Findlay D; Holmes C; Johnson T; Jones R; Katona C; Lindesay J; Macharouthu A; McKeith I; McShane R; O'Brien JT; Phillips PPJ; Sheehan B; Howard R
Int J Geriatr Psychiatry; 2017 Dec; 32(12):1205-1216. PubMed ID: 27739182
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.
Hartz S; Getsios D; Tao S; Blume S; Maclaine G
BMC Neurol; 2012 Feb; 12():2. PubMed ID: 22316501
[TBL] [Abstract][Full Text] [Related]
12. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.
Teipel SJ; Ewers M; Reisig V; Schweikert B; Hampel H; Happich M
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):330-6. PubMed ID: 17404699
[TBL] [Abstract][Full Text] [Related]
13. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.
Wimo A; Winblad B; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Mastey V; Haglund A; Zhang R; Miceli R; Chin W; Subbiah P;
Dement Geriatr Cogn Disord; 2003; 15(1):44-54. PubMed ID: 12457078
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Hux M; Xu Y; Schwam EM; Shah S; Mastey V;
Neurology; 2004 Aug; 63(4):644-50. PubMed ID: 15326236
[TBL] [Abstract][Full Text] [Related]
15. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Courtney C; Farrell D; Gray R; Hills R; Lynch L; Sellwood E; Edwards S; Hardyman W; Raftery J; Crome P; Lendon C; Shaw H; Bentham P;
Lancet; 2004 Jun; 363(9427):2105-15. PubMed ID: 15220031
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
[TBL] [Abstract][Full Text] [Related]
17. Donepezil. Pharmacoeconomic implications of therapy.
Foster RH; Plosker GL
Pharmacoeconomics; 1999 Jul; 16(1):99-114. PubMed ID: 10539126
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan.
Ikeda S; Yamada Y; Ikegami N
Dement Geriatr Cogn Disord; 2002; 13(1):33-9. PubMed ID: 11731713
[TBL] [Abstract][Full Text] [Related]
19. AD2000: donepezil in Alzheimer's disease.
Schneider LS
Lancet; 2004 Jun; 363(9427):2100-1. PubMed ID: 15220027
[No Abstract] [Full Text] [Related]
20. An economic evaluation of donepezil in the treatment of Alzheimer's disease.
Small GW; Donohue JA; Brooks RL
Clin Ther; 1998; 20(4):838-50. PubMed ID: 9737841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
